Biosimilars of monoclonal antibodies against TNF-alpha have dramatically reduced the costs of these therapies for the treatment of Inflammatory bowel disease (IBD), and represent a valid option to induce and maintain remission in Crohn’s Disease (CD) and Ulcerative Colitis (UC). Some concerns have been raised about their efficacy, safety and immunogenicity compared to their reference medicine molecule in the recent past. Increasing evidence supports the clinical equivalence of biosimilars together with a huge significant cost saving, although many clinicians appear to be reluctant to get confidence in the use of biosimilars of anti-TNF agents.
This webinar will give an overview on the role of biosimilars in IBD patients, and will discuss some key points on how to get correct information and how to use biosimilars in everyday’s clinical practice.